You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


EMA accepts application for leukaemia drug from Otsuka and Astex

The European Medicines Agency (EMA) has accepted Otsuka Pharmaceutical and Astex Pharmaceuticals’ marketing authorisation application (MAA) for an oral fixed-dose combination of decitabine and cedazuridine.